Is Novartis' Dividend Safe?

Novartis (NYSE: NVS  ) is one of the globe's biggest drug companies. The company generates more than $58 billion in annual sales and is often included in dividend investors' portfolios.

Novartis has a solid track record of dividend increases over the past decade; however, investors are right to wonder whether patent expiration on its top-selling blockbuster drug Diovan may threaten Novartis' ability to boost dividends in the future.

In the following slideshow you'll learn whether I think Novartis' dividend is safe and see how Novartis' dividend matches up to peers GlaxoSmithKline (NYSE: GSK  ) , Novartis' partner in a new consumer goods joint ventures, and Sanofi (NYSE: SNY  ) , a company that competes with Novartis top selling MS drug Gilenya.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3006640, ~/Articles/ArticleHandler.aspx, 12/18/2014 11:04:37 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement